<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00966771</url>
  </required_header>
  <id_info>
    <org_study_id>30937</org_study_id>
    <secondary_id>1R21HD063028-01A1</secondary_id>
    <nct_id>NCT00966771</nct_id>
  </id_info>
  <brief_title>The Copper T380A IUD vs. Oral Levonorgestrel for Emergency Contraception</brief_title>
  <acronym>IUD EC</acronym>
  <official_title>Preventing Future Pregnancy After Choosing the Copper IUD vs. Oral Levonorgestrel for Emergency Contraception</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Society of Family Planning</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if women presenting for emergency contraception (EC) and&#xD;
      choose the copper intrauterine device (IUD) will have fewer unplanned pregnancies in the next&#xD;
      year compared to women who choose oral levonorgestrel for EC. The study will also compare use&#xD;
      of an effective method of contraception in the year after they received EC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All women presenting to 2 Planned Parenthood Association of Utah clinics in Salt Lake City&#xD;
      will be offered participation in this study. Women will select either the copper IUD or oral&#xD;
      levonorgestrel for EC. The primary outcome is unplanned pregnancy in the year following&#xD;
      presentation for EC.&#xD;
&#xD;
      Secondary outcomes include use of an effective method of contraception over the next year,&#xD;
      abortions, repeat use of EC, number of days to first bleeding episode and duration of that&#xD;
      bleeding episode, use of a barrier method to prevent sexually transmitted infections, patient&#xD;
      satisfaction with the chosen method of EC and contraception. Participants selecting the IUD&#xD;
      will be assessed for IUD expulsion, perforation, and removal.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Unplanned pregnancy</measure>
    <time_frame>within 12 months of presenting for EC</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Use of an effective method of contraception in the year following use of emergency contraception.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IUD expulsion, removal or perforation</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">548</enrollment>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>IUD</arm_group_label>
    <description>Women presenting for emergency contraception who select the copper IUD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral levonorgestrel</arm_group_label>
    <description>Women presenting for emergency contraception who select oral levonorgestrel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Copper T380 IUD</intervention_name>
    <description>copper T 380 IUD</description>
    <arm_group_label>IUD</arm_group_label>
    <other_name>Paragard IUD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral levonorgestrel</intervention_name>
    <description>1.5 mg</description>
    <arm_group_label>Oral levonorgestrel</arm_group_label>
    <other_name>Plan B</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women presenting to family planning clinics for emergency contraception&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women 18-30 years old,&#xD;
&#xD;
          -  in need of emergency contraception (had unprotected intercourse within 120 hours),&#xD;
&#xD;
          -  willing to give consent for participation in research,&#xD;
&#xD;
          -  willing to comply with study requirements, and&#xD;
&#xD;
          -  accessible by telephone.&#xD;
&#xD;
        Participants selecting the IUD need to identify themselves as desiring long-term&#xD;
        contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current pregnancy&#xD;
&#xD;
          -  Had pelvic inflammatory disease or septic abortion within the past 3 months or had&#xD;
             gonorrhea or chlamydia infection in the last 60 days&#xD;
&#xD;
          -  Current behavior suggesting a high risk for pelvic inflammatory disease&#xD;
&#xD;
          -  Allergy to copper or Wilson's disease (for participants selecting the copper IUD) or&#xD;
             allergy to levonorgestrel (for participants selecting oral levonorgestrel)&#xD;
&#xD;
          -  Abnormalities of the uterus that distort the uterine cavity&#xD;
&#xD;
          -  Mucopurulent cervicitis&#xD;
&#xD;
          -  A previously placed IUD that has not been removed&#xD;
&#xD;
          -  Genital bleeding of an unknown etiology&#xD;
&#xD;
          -  Ovarian, cervical, or endometrial cancer&#xD;
&#xD;
          -  Small uterine cavity (&lt; 6cm)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Turok, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Planned Parenthood Association of Utah Salt Lake City Clinic</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84102-3430</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Planned Parenthood Association of Utah, West Valley City Clinic</name>
      <address>
        <city>West Valley City</city>
        <state>Utah</state>
        <zip>84119-4715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>August 25, 2009</study_first_submitted>
  <study_first_submitted_qc>August 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2009</study_first_posted>
  <last_update_submitted>February 2, 2017</last_update_submitted>
  <last_update_submitted_qc>February 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>David Turok</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>contraception</keyword>
  <keyword>emergency contraception</keyword>
  <keyword>pregnancy prevention after unprotected intercourse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emergencies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Copper</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

